WO2003104282A3 - Glycoprotein vi - fc fusion protein for treating vascular disorders - Google Patents

Glycoprotein vi - fc fusion protein for treating vascular disorders Download PDF

Info

Publication number
WO2003104282A3
WO2003104282A3 PCT/EP2003/005929 EP0305929W WO03104282A3 WO 2003104282 A3 WO2003104282 A3 WO 2003104282A3 EP 0305929 W EP0305929 W EP 0305929W WO 03104282 A3 WO03104282 A3 WO 03104282A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
glycoprotein
vascular disorders
treating vascular
provides
Prior art date
Application number
PCT/EP2003/005929
Other languages
French (fr)
Other versions
WO2003104282A2 (en
WO2003104282A8 (en
Inventor
Steffen Massberg
Meinrad Gawaz
Andreas Bueltmann
Goetz Muench
Martin Ungerer
Mario Peluso
Original Assignee
Procorde Gmbh
Steffen Massberg
Meinrad Gawaz
Andreas Bueltmann
Goetz Muench
Martin Ungerer
Mario Peluso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60309865T priority Critical patent/DE60309865T2/en
Priority to CA2488630A priority patent/CA2488630C/en
Priority to SI200330640T priority patent/SI1511770T1/en
Priority to AU2003236704A priority patent/AU2003236704B2/en
Application filed by Procorde Gmbh, Steffen Massberg, Meinrad Gawaz, Andreas Bueltmann, Goetz Muench, Martin Ungerer, Mario Peluso filed Critical Procorde Gmbh
Priority to EP03735562A priority patent/EP1511770B1/en
Priority to CN038172798A priority patent/CN1668721B/en
Priority to US10/489,053 priority patent/US7514543B2/en
Priority to JP2004511349A priority patent/JP4722480B2/en
Publication of WO2003104282A2 publication Critical patent/WO2003104282A2/en
Publication of WO2003104282A8 publication Critical patent/WO2003104282A8/en
Publication of WO2003104282A3 publication Critical patent/WO2003104282A3/en
Priority to US11/009,106 priority patent/US7531178B2/en
Priority to US11/792,857 priority patent/US20090130021A1/en
Priority to US11/446,537 priority patent/US20070071744A1/en
Priority to US12/355,689 priority patent/US8119135B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in Figure 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.
PCT/EP2003/005929 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein vi domain WO2003104282A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN038172798A CN1668721B (en) 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein VI domain
SI200330640T SI1511770T1 (en) 2002-06-07 2003-06-05 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
AU2003236704A AU2003236704B2 (en) 2002-06-07 2003-06-05 Glycoprotein VI - FC fusion protein for treating vascular disorders
JP2004511349A JP4722480B2 (en) 2002-06-07 2003-06-05 Immunoadhesins containing glycoprotein VI domains
EP03735562A EP1511770B1 (en) 2002-06-07 2003-06-05 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
CA2488630A CA2488630C (en) 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein vi domain
US10/489,053 US7514543B2 (en) 2002-06-07 2003-06-05 Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain
DE60309865T DE60309865T2 (en) 2002-06-07 2003-06-05 GLYCOPROTEIN VI - FC FUSION PROTEIN FOR THE TREATMENT OF VASCULAR DISEASES
US11/009,106 US7531178B2 (en) 2002-06-07 2004-12-10 Immunoadhesin comprising a glycoprotein VI domain
US11/792,857 US20090130021A1 (en) 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature
US11/446,537 US20070071744A1 (en) 2002-06-07 2006-06-02 Agents which bind to epitopes of glycoprotein VI
US12/355,689 US8119135B2 (en) 2002-06-07 2009-01-16 Antibodies which bind to epitopes of glycoprotein VI

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012742.9 2002-06-07
EP02012742A EP1369128A1 (en) 2002-06-07 2002-06-07 Inhibitors of glycoprotein VI and their therapeutic use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10489053 A-371-Of-International 2003-06-05
US11/009,106 Continuation-In-Part US7531178B2 (en) 2002-06-07 2004-12-10 Immunoadhesin comprising a glycoprotein VI domain

Publications (3)

Publication Number Publication Date
WO2003104282A2 WO2003104282A2 (en) 2003-12-18
WO2003104282A8 WO2003104282A8 (en) 2004-04-29
WO2003104282A3 true WO2003104282A3 (en) 2004-10-14

Family

ID=29433140

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/005929 WO2003104282A2 (en) 2002-06-07 2003-06-05 Immunoadhesin comprising a glycoprotein vi domain
PCT/EP2003/005919 WO2003103662A2 (en) 2002-06-07 2003-06-05 Inhibitors of glycoprotein vi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005919 WO2003103662A2 (en) 2002-06-07 2003-06-05 Inhibitors of glycoprotein vi

Country Status (13)

Country Link
US (1) US7514543B2 (en)
EP (4) EP1369128A1 (en)
JP (1) JP4722480B2 (en)
CN (1) CN1668721B (en)
AT (1) ATE346095T1 (en)
AU (2) AU2003250825A1 (en)
CA (1) CA2488630C (en)
DE (1) DE60309865T2 (en)
DK (1) DK1860118T3 (en)
ES (2) ES2276078T3 (en)
SI (1) SI1511770T1 (en)
WO (2) WO2003104282A2 (en)
ZA (1) ZA200409776B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
WO2006061650A2 (en) * 2004-12-10 2006-06-15 Trigen Gmbh Methods, products and uses involving platelets and/or the vasculature
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
CN1964990B (en) * 2004-04-29 2012-12-12 大冢制药株式会社 Antibodies specific for glycoprotein VI and methods of producing these antibodies
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
ES2534288T3 (en) 2004-08-03 2015-04-21 Innate Pharma Therapeutic compositions against cancer that target 4Ig-B7-H3
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
WO2006117910A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
JP5224707B2 (en) * 2005-04-28 2013-07-03 持田製薬株式会社 Anti-platelet membrane glycoprotein VI monoclonal antibody
EP1876240B1 (en) * 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody
KR20080078675A (en) * 2005-12-22 2008-08-27 시오노기 앤드 컴파니, 리미티드 Method for prediction of prognosis of acute coronary syndrome
WO2009058326A1 (en) * 2007-10-31 2009-05-07 Otsuka Pharmaceutical Co., Ltd. Uses of a glycoprotein vi (gpvi) inhibitor
JP5863459B2 (en) * 2008-12-04 2016-02-16 インセルム （アンスティテュ・ナショナル・ドゥ・ラ・サント・エ・ドゥ・ラ・ルシェルシュ・メディカル）ＩＮＳＥＲＭ （Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ ｄｅ ｌａ Ｓａｎｔｅ ｅｔ ｄｅ ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） Platelet production method
US10907209B2 (en) * 2009-05-15 2021-02-02 University Health Network Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
SG181707A1 (en) * 2009-12-18 2012-07-30 Sanofi Sa Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2377888A1 (en) 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
DK3575326T3 (en) 2012-12-17 2022-05-30 Pf Argentum Ip Holdings Llc Treatment of CD47 + disease cells with SIRP ALFA-FC fusions
AU2013364840B2 (en) * 2012-12-20 2017-03-16 Fujimori Kogyo Co., Ltd. Method for comprehensive assessment of platelet aggregation
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
JP2023513135A (en) * 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Polypeptides useful for detecting anti-rhabdovirus antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000810A1 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
US6383779B1 (en) * 1999-06-30 2002-05-07 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
CZ302693B6 (en) 1999-05-07 2011-09-07 Aventis Pharma Deutschland Gmbh Recombinant human glycoprotein VI, DNA coding therefor and pharmaceutical composition containing thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
AU2002312059B2 (en) 2001-05-25 2009-01-15 Duke University Modulators of pharmacological agents
CA2453986A1 (en) 2001-07-18 2003-01-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000810A1 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
US6383779B1 (en) * 1999-06-30 2002-05-07 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JANDROT-PERRUS MARTINE ET AL: "Cloning, characterization, and functional studies of human and mouse glycoprotein VI: A platelet-specific collagen receptor from the immunoglobulin superfamily", BLOOD, vol. 96, no. 5, 1 September 2000 (2000-09-01), pages 1798 - 1807, XP002259594, ISSN: 0006-4971 *
MASSBERG STEFFEN ET AL: "Platelet-endothelial cell interactions during ischemia/reperfusion: The role of P-selectin", BLOOD, vol. 92, no. 2, 15 July 1998 (1998-07-15), pages 507 - 515, XP002260613, ISSN: 0006-4971 *
NIESWANDT BERNHARD ET AL: "Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 9, 1 May 2001 (2001-05-01), pages 2120 - 2130, XP002241738, ISSN: 0261-4189 *
NIESWANDT BERNHARD ET AL: "Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.", JOURNAL EXP. MED., vol. 193, no. 4, 19 February 2001 (2001-02-19), The rockefeller university press., pages 459 - 469, XP002241737, ISSN: 0022-1007 *
ROSENFELD MICHAEL E ET AL: "Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research.", CURRENT ATHEROSCLEROSIS REPORTS. UNITED STATES MAY 2002, vol. 4, no. 3, May 2002 (2002-05-01), pages 238 - 242, XP002260664, ISSN: 1523-3804 *
VINIK A I ET AL: "Platelet dysfunction in type 2 diabetes.", DIABETES CARE. UNITED STATES AUG 2001, vol. 24, no. 8, August 2001 (2001-08-01), pages 1476 - 1485, XP002258558, ISSN: 0149-5992 *

Also Published As

Publication number Publication date
AU2003236704A1 (en) 2003-12-22
ZA200409776B (en) 2007-02-28
CN1668721B (en) 2012-11-14
US7514543B2 (en) 2009-04-07
DE60309865D1 (en) 2007-01-04
JP2006512894A (en) 2006-04-20
US20050079541A1 (en) 2005-04-14
AU2003250825A8 (en) 2003-12-22
DK1860118T3 (en) 2015-02-09
DE60309865T2 (en) 2007-10-18
ES2527717T3 (en) 2015-01-28
WO2003104282A2 (en) 2003-12-18
EP1860118A3 (en) 2008-07-30
WO2003103662A3 (en) 2004-11-04
AU2003236704B2 (en) 2010-07-08
WO2003104282A8 (en) 2004-04-29
CA2488630C (en) 2011-07-05
CN1668721A (en) 2005-09-14
AU2003250825A1 (en) 2003-12-22
ATE346095T1 (en) 2006-12-15
JP4722480B2 (en) 2011-07-13
CA2488630A1 (en) 2003-12-18
EP1369128A1 (en) 2003-12-10
EP1860118B1 (en) 2014-12-31
WO2003103662A2 (en) 2003-12-18
EP1511480A2 (en) 2005-03-09
SI1511770T1 (en) 2007-04-30
ES2276078T3 (en) 2007-06-16
EP1511770A2 (en) 2005-03-09
EP1511770B1 (en) 2006-11-22
EP1860118A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
WO2003104282A3 (en) Glycoprotein vi - fc fusion protein for treating vascular disorders
ME00185B (en) Specific binding agents of human angiopoietin-2
DE69534588D1 (en) PROTOCADHERINE PROTEINS AND USES THEREOF
ATE496063T1 (en) HYBRID AND TANDEM PROTEINS FROM NEISSERIA SP
DE60121808D1 (en) USE OF A POLYPEPTIDE CONTAINING THE EXTRACELLULAR DOMAIN OF IL-20RA AND IL-20RB FOR THE TREATMENT OF INFLAMMATION
ATE223229T1 (en) COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEIN WITH THE FC CHAIN OF IMMUNOGLOBULINS AND RELATED METHODS
DK1144607T3 (en) Process for presenting (poly) peptides / proteins on bacteriophage particles via disulfide bonds
ATE352617T1 (en) SOLUBLE POLYPEPTIDE FRACTIONS OF LAG-3 PROTEIN; METHOD OF PRODUCTION; THERAPEUTIC COMPOSITION; ANTIDIOTYPICAL ANTIBODIES
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
ATE459004T1 (en) LIGAND FOR THE FORMYLPEPTIDE RECEPTOR-LIKE-2 (FPRL2) G PROTEIN-COUPLED RECEPTOR AND ITS APPLICATION
DK1129186T3 (en) A factor VIII polypeptide having factor VIII: C activity
DE69915320D1 (en) IMMUNOGLOBULIN-BINDING PROTEINS
DE59711375D1 (en) METHOD FOR ACTIVATING DENATURED PROTEIN
WO2007052067A3 (en) Von willebrand factor (vwf) binding peptides
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
ATE416260T1 (en) METHOD FOR MONITORING AND MODULATING PROTEIN FOLDING
ATE414164T1 (en) METHOD FOR CONTROLLING CLEAVAGE USING OMPT PROTEASE
ATE367438T1 (en) METHOD FOR INCREASE HUMAN TNF RECEPTOR EXPRESSION
WO2004007536A3 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
EP1467207A4 (en) Screening method
NZ501161A (en) Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 51/2003 UNDER (72, 75) ADD "PELUSO, MARIO"

WWE Wipo information: entry into national phase

Ref document number: 10489053

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003735562

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 693/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004/09776

Country of ref document: ZA

Ref document number: 200409776

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2488630

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004511349

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003236704

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038172798

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003735562

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003735562

Country of ref document: EP